What exactly is Progressive Multifocal Leukoencephalopathy (PML), other than a long and complicated phrase? How does one get it and what exactly is the risk of getting this with different…
Join RMMSC Medical Director Dr. Timothy Vollmer for an in-depth look at disease modifying therapies (DMTs) – the front line in our fight against MS. This webinar will give you…
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live Q&A, Dr. Enrique Alvarez answers some common questions on…
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live Q&A, Dr. Timothy Vollmer answers some common questions on…
Did you know that in terms of medication, multiple sclerosis is the second most expensive chronic disease to treat? Health-related costs average $57,500 per year with lifetime costs of more…
Laquinimod Laquinimod is an investigational, oral, once-daily therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). The therapy (licensed to Teva Neuroscience) received Fast Track designation—meaning the therapy demonstrated the…